Entrada Therapeutics, Inc.
TRDA
$11.88
-$0.71-5.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -143.75M | -103.46M | -73.35M | 24.78M | 65.63M |
| Total Depreciation and Amortization | 4.10M | 4.20M | 3.91M | 3.79M | 3.77M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.94M | 14.41M | 11.68M | 9.95M | 7.90M |
| Change in Net Operating Assets | -4.80M | -43.07M | -66.10M | -93.06M | -118.85M |
| Cash from Operations | -128.51M | -127.91M | -123.87M | -54.55M | -41.56M |
| Capital Expenditure | -1.04M | -1.88M | -2.69M | -3.46M | -3.16M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 117.85M | 142.94M | 11.71M | -45.70M | -24.64M |
| Cash from Investing | 116.81M | 141.05M | 9.02M | -49.16M | -27.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 887.00K | 2.10M | 2.09M | 103.12M | 102.98M |
| Repurchase of Common Stock | -- | -- | -11.00K | -11.00K | -11.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 887.00K | 2.10M | 2.08M | 103.11M | 102.96M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.82M | 15.24M | -112.77M | -599.00K | 33.61M |